Skip to main content

Neurofibromatosis 2

3
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD2014Phase 21 trial
Active Trials
NCT02831257Completed18Est. Oct 2020
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
LapatinibPhase 2Small Molecule
Cochlear
CochlearAustralia - Macquarie Park
1 program
1
Multichannel Auditory Brain Stem ImplantPhase 21 trial
Active Trials
NCT00004437CompletedEst. Oct 2000
GSK
GSKLONDON, United Kingdom
1 program
LapatinibPHASE_2Small Molecule1 trial
Active Trials
NCT00973739Completed21Est. Nov 2012
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
PTC299PHASE_21 trial
Active Trials
NCT00911248Terminated11Est. Mar 2012
PTC Therapeutics
1 program
PTC299PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaAZD2014
GSKLapatinib
United TherapeuticsPTC299
CochlearMultichannel Auditory Brain Stem Implant

Clinical Trials (4)

Total enrollment: 50 patients across 4 trials

NCT02831257AstraZenecaAZD2014

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Start: Aug 2016Est. completion: Oct 202018 patients
Phase 2Completed
NCT00973739GSKLapatinib

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Start: Sep 2009Est. completion: Nov 201221 patients
Phase 2Completed
NCT00911248United TherapeuticsPTC299

PTC299 for Treatment of Neurofibromatosis Type 2

Start: Jul 2009Est. completion: Mar 201211 patients
Phase 2Terminated
NCT00004437CochlearMultichannel Auditory Brain Stem Implant

Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2

Start: Oct 1999Est. completion: Oct 2000
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.